Retaane® in Age-Related Macular Degeneration
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 主要终点
- Increase in VA
研究概览
简要总结
The treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration currently presents a great challenge. With visual loss threatening, there are only very few therapeutic options.
While these patients are neither suitable for laser therapy nor for photodynamic therapy with Verteporfin, antiangiogenic drugs applied intravitreally are now available.
Some patients however reject this therapeutic option because of potential complications such as endophthalmitis and the frequency of necessary injections. 20 patients who rejected intravitreal therapy were treated with Anecortave acetate (Retaane®) which was applied as a juxtascleral depot injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •rejection of intravitreal injections
- •presence of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration
排除标准
- •conditions precluding judgement of the fundus
研究组 & 干预措施
1
Patients treated with Retaane
干预措施: juxtascleral depot injection of Retaane (Drug)
结局指标
主要结局
Increase in VA
时间窗: 6 months
次要结局
- Decrease in Macula Edema(6 months)